Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Total Voting Rights

31 Dec 2025 13:00

RNS Number : 1927N
Frontier IP Group plc
31 December 2025
 

31 December 2025

 

Frontier IP Group plc

("Frontier IP", the "Company" or the "Group")

 

Total Voting Rights

 

Frontier IP Group plc (AIM: FIPP), a specialist in commercialising intellectual property, announces that the issued share capital of the Company at the date of this announcement comprises 75,638,239 ordinary shares of 10 pence each in the Company ("Ordinary Shares"), with one voting right per Ordinary Share. The Company does not hold any Ordinary Shares in treasury, therefore the total number of Ordinary Shares and voting rights in the Company is 75,638,239.

 

The above figure of 75,638,239 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

ENQUIRIES

 

Frontier IP Group Plc

Neil Crabb, Chief Executive

 

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

 

neil@frontierip.co.uk

 

M: 07464 546 025

andrew.johnson@frontierip.co.uk

 

Allenby Capital Limited (Nominated Adviser)

Nick Athanas

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Charles Leigh-Pemberton / James Fischer

T: 0207 496 3000

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRBLBDDCDXDGUG
Date   Source Headline
9th Dec 20212:33 pmRNSResult of AGM
29th Nov 20217:00 amRNSTVG - milestone in development of COVID-19 vaccine
9th Nov 20217:00 amRNSPosting of Annual Accounts and Notice of AGM
28th Oct 20217:00 amRNSDirectorate Change
28th Oct 20217:00 amRNSFinal Results
15th Oct 20217:00 amRNSPublication of newsletter
1st Oct 20217:59 amRNSPricing of IPO of Exscientia in the United States
30th Sep 20217:00 amRNSCamGraPhIC raises £1.6 million
27th Sep 20213:56 pmRNSUpdate on proposed IPO of Exscientia
24th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20217:00 amRNSExscientia - Statement filed for proposed IPO
8th Sep 20211:24 pmRNSExscientia enters $70M collaboration
8th Jul 20217:00 amRNSCamGraPhIC loan facility of up to £1.5 million
15th Jun 20217:00 amRNSPulsiv appoints Adam Westcott as CFO
14th Jun 20217:00 amRNSNandi Proteins appoints David Flower as CEO
11th Jun 20217:00 amRNSPublication of newsletter
24th May 20217:00 amRNSPulsiv complete £1.5m fundraising and appoints CEO
19th May 202111:53 amRNSExscientia collaboration with Bristol Myers Squibb
6th May 20217:00 amRNSThe Vaccine Group appoints Jeremy Salt as CEO
30th Apr 20211:58 pmRNSHolding(s) in Company
28th Apr 20217:01 amRNSTrading update
28th Apr 20217:00 amRNSExscientia Series D funding led by SoftBank
20th Apr 20217:00 amRNSHolding(s) in Company
24th Mar 20217:00 amRNSUnaudited Half Year Results
19th Mar 20217:00 amRNSFieldwork Robotics raises £675,000
18th Mar 20217:00 amRNSHolding(s) in Company
16th Mar 20217:00 amRNSAlusid - appoints David Taylor CBE to the Board
12th Mar 202112:27 pmRNSHolding(s) in Company
12th Mar 20217:00 amRNSHolding(s) in Company
11th Mar 20217:00 amRNSinSignals Neurotech receives EUR100,000 investment
9th Mar 20217:00 amRNSUN awards $250,000 grant to AquaInSilico
8th Mar 20219:05 amRNSSecond Price Monitoring Extn
8th Mar 20219:00 amRNSPrice Monitoring Extension
4th Mar 20217:30 amRNSExscientia completes $100 million Series C funding
22nd Feb 20217:00 amRNSPulsiv Solar raises £890,000
16th Feb 20217:00 amRNSPublication of newsletter
16th Feb 20217:00 amRNSHolding(s) in Company
1st Feb 20217:00 amRNSFrontier IP supports breakthrough technology
18th Jan 20217:00 amRNSHolding(s) in Company
15th Jan 20217:00 amRNSAppointment of Darren Winter
11th Jan 20217:00 amRNSPortfolio news – Elute Intelligence raises £250k
29th Dec 20201:44 pmRNSHolding(s) in Company
17th Dec 202012:30 pmRNSResult of AGM
1st Dec 20207:00 amRNSCambridge Raman participates in EUR 5m project
20th Nov 20207:00 amRNSPosting of Annual Report and Notice of AGM
16th Nov 20207:00 amRNSFrontier IP: recording of annual results webcast
16th Nov 20207:00 amRNSPortfolio news – Fieldwork SIF grant
13th Nov 20202:03 pmRNSHolding(s) in Company
10th Nov 20207:00 amRNSAlusid - £125,000 backing from UK Future Fund
9th Nov 20206:03 pmRNSDirectors’ Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.